Alpha Mannosidosis Market Report: Size, Growth, Share, Trends, Competitive Landscape, Forecast To 2033

The new report published by The Business Research Company, titled Alpha Mannosidosis Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the alpha mannosidosis market size has grown rapidly in recent years. It will grow from $12.77 billion in 2023 to $15.26 billion in 2024 at a compound annual growth rate (CAGR) of 19.5%. The alpha mannosidosis market size is expected to see rapid growth in the next few years. It will grow to $29.62 billion in 2028 at a compound annual growth rate (CAGR) of 18.0%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=4093&type=smp

Elevated Regulatory Backing Fuels Growth In Alpha Mannosidosis Market
Rising regulatory support for the drug approval of rare diseases in alpha mannosidosis is expected to drive the market in the forecast period. The inherently small population of patients with a rare disease can also make conducting clinical trials difficult. But to tackle this, in 2021, the FDA announced providing support for the development and evaluation of new treatments for rare diseases making it a key priority. The FDA has the authority to grant orphan-drug designation to a drug or biological product to prevent, diagnose, or treat a rare disease or condition. Orphan drug designation qualifies sponsors for incentives including tax credits for qualified clinical trials, exemption from user fees, and potential seven years of market exclusivity after approval. Thus, the rising support for regulatory bodies will propel the market.

Focus On Enzyme Replacement Therapy Drives Innovation In The Alpha Mannosidosis Market
Major companies operating in the alpha mannosidosis market are focusing on developing enzyme replacement therapy for rare alpha-mannosidosis. By supplying exogenous alpha-mannosidase, enzyme replacement therapy helps reduce the accumulation of mannose-rich oligosaccharides in various tissues and organs. This accumulation is a characteristic feature of alpha-mannosidosis and contributes to the disease's pathological effects. For instance, in February 2023, Chiesi Global Rare Diseases a US-based pharmaceutical company launched Lamzede (velmanase alfa), the first enzyme replacement therapy authorized in the United States for the treatment of alpha-mannosidosis, a rare genetic condition marked by an absence of the enzyme alpha-mannosidase in the body, and its manifestations outside of the central nervous system. Lamzede restores normal cellular activity in patients by acting in the same manner as the human body's alpha-mannosidase enzyme. Once a week, patients receive an injection of 10 mg of Lamzede.

The alpha mannosidosis market covered in this report is segmented -

1) By Therapy Type: Bone Marrow Transplant (BMT), Enzyme Replacement Therapy (ERT), Other Therapies
2) By Indication: Type I, Type II, Type III
3) By End-User: Hospitals, Speciality Clinics

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=4093&type=discount

Major companies operating in the alpha mannosidosis market report are Chiesi Farmaceutici S.p.A., Cipla, EdiGene Inc., Immunochina, Takara Bio, Daiichi Sankyo Company, Ultragenyx Pharmaceutical Inc, Mitsubishi Tanabe Pharma, Oxford Biomedica plc, Santen Pharmaceutical Co., Merck, GenScript, Cellular Biomedicine Group, GE Healthcare, Lonza, Nikon CeLL innovation Co. Ltd., Gilead Sciences, Bristol-Myers Squibb, Novartis AG, Amgen, Centogene, Zymenex A/S, Albumedix Ltd, Kite Pharma, Catalent, Freeline Therapeutics, Avectas, DiNAQOR AG, Vivet Therapeutics, Allergan, PsiOxus Therapeutics, Herantis Pharma Plc, Biocad, Celgene Corporation, Johnson & Johnson, F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Bayer AG, Lyric Opera of Chicago, AMC Entertainment Holdings Inc, Regal Entertainment Group, Carmike Cinemas Inc, Ultragenyx, PTC Therapeutics, Gilead Sciences Inc., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Pfizer S.R.L., AstraZeneca plc, Biotchpharma, Gene Vector Technologies, BrainStorm Cell Therapeutics, Pluristem, Biogen SA, Sanofi, Adcock Ingram

Contents of the report:
1. Executive Summary
2. Alpha Mannosidosis Market Report Structure
3. Alpha Mannosidosis Market Trends And Strategies
4. Alpha Mannosidosis Market - Macro Economic Scenario
5. Alpha Mannosidosis Market Size And Growth
…..
27. Alpha Mannosidosis Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/alphas-mannosidosis-global-market-report

Contact us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Latest Trending Press Releases: https://www.thebusinessresearchcompany.com/press-release.aspx

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.